NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 4.2% – Time to Sell?

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) traded down 4.2% on Friday . The company traded as low as $0.4201 and last traded at $0.4204. 95,020 shares traded hands during trading, a decline of 77% from the average daily volume of 411,943 shares. The stock had previously closed at $0.4389.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Down 4.2%

The stock’s 50 day moving average price is $0.58 and its 200-day moving average price is $0.73. The stock has a market capitalization of $15.88 million, a P/E ratio of -0.78 and a beta of 1.62.

Insider Activity

In related news, CFO Or Eisenberg bought 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Alon Ben-Noon bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 27.40% of the stock is owned by insiders.

Institutional Trading of NeuroSense Therapeutics

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new position in shares of NeuroSense Therapeutics in the third quarter valued at about $26,000. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics during the 2nd quarter worth $54,000. Yorkville Advisors Global LP purchased a new position in NeuroSense Therapeutics during the second quarter worth about $56,160. Finally, Squarepoint Ops LLC grew its position in NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.